Changing Face Of ‘Me Too’ Drugs On Display In 2014 NME Approvals
Executive Summary
As the era of the primary care blockbusters waned, pharma R&D shifted toward less price-sensitive specialty fields. Now successful specialty drug development is producing its own sort of follow-on agents, and payers are pushing back. Even oncology is not immune.
You may also be interested in...
J.P. Morgan Notebook, Jan. 12: Biogen, Novartis, Celgene
Welcome to “The Pink Sheet” DAILY’s round-up of news and notes from the first day of the 2015 J.P. Morgan Healthcare Conference in San Francisco.
Biologics’ Big Bang: Novel BLAs Balance Breakthroughs And ‘Biobetters’
Both FDA’s biologics and drug centers posted historic BLA approval counts in 2014, combining to clear 21 novel biologics. The class is split between medical breakthroughs and “biobetters” offering incremental improvements, illustrating the maturation of the biotech industry.
Head Of The Class: A Star Stands Out Among 2014 Drug Launches
Gilead’s Sovaldi earned a spot in the record books – and the hearts of drug marketers – generating $8.55 billion in the first nine months of 2014. Despite controversy over Sovaldi’s high price, Gilead defended the drug’s value and executed flawlessly on the launch. Other 2014 drug launches were slow out of the gates, as the bar for new drugs continues to grow.